Orthopaedics

The present Competitive Intelligence Report about growth factors for bone, dental, cartilage and tendon repair provides a competitor evaluation in the field of molecules such as proteins, peptides, antibodies and small molecules stimulating growth of bone, dental, cartilage and soft tissue such as tendons as of December 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Bone morphogenetic protein 2 (rhBMP-2) iss approved by the Food and Drug Administration for anterior lumbar interbody fusion and for acute open tibial fractures; rhBMP-7, on the other hand, is approved for long bone defects and has received a humanitarian device exemption for revision posterolateral lumbar operations and recalcitrant long bone unions. The commercial success of BMP-2 has spurred the clinical evaluation in many other subsets of bone defects and the research into new growth factors and scaffolds. The first products were also approved for use in dental implantation procedures extending the scope of indications for bone and dental growth factors.